BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29789417)

  • 21. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
    Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
    Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
    Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
    Front Immunol; 2020; 11():1981. PubMed ID: 32983136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
    Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
    Backert L; Kowalewski DJ; Walz S; Schuster H; Berlin C; Neidert MC; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Kanz L; Salih HR; Kohlbacher O; Weisel K; Rammensee HG; Stevanovic S; Walz JS
    Oncotarget; 2017 Jul; 8(27):43915-43924. PubMed ID: 28159928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
    Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
    Front Immunol; 2021; 12():662443. PubMed ID: 33936100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.
    Walz S; Stickel JS; Kowalewski DJ; Schuster H; Weisel K; Backert L; Kahn S; Nelde A; Stroh T; Handel M; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S
    Blood; 2015 Sep; 126(10):1203-13. PubMed ID: 26138685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
    Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
    Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.
    Marcilla M; Alpízar A; Lombardía M; Ramos-Fernandez A; Ramos M; Albar JP
    Mol Cell Proteomics; 2014 Feb; 13(2):462-74. PubMed ID: 24366607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
    Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
    Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability.
    Cleyle J; Hardy MP; Minati R; Courcelles M; Durette C; Lanoix J; Laverdure JP; Vincent K; Perreault C; Thibault P
    Mol Cell Proteomics; 2022 May; 21(5):100228. PubMed ID: 35367648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
    Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
    Elife; 2020 Apr; 9():. PubMed ID: 32314731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.
    Park J; Talukder AH; Lim SA; Kim K; Pan K; Melendez B; Bradley SD; Jackson KR; Khalili JS; Wang J; Creasy C; Pan BF; Woodman SE; Bernatchez C; Hawke D; Hwu P; Lee KM; Roszik J; Lizée G; Yee C
    Cancer Immunol Res; 2017 Aug; 5(8):618-629. PubMed ID: 28630054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
    Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells.
    Schwarz S; Schmitz J; Löffler MW; Ghosh M; Rammensee HG; Olshvang E; Markel M; Mockel-Tenbrinck N; Dzionek A; Krake S; Arslan B; Kampe KD; Wendt A; Bauer P; Mullins CS; Schlosser A; Linnebacher M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
    Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
    Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
    Miyamoto S; Kochin V; Kanaseki T; Hongo A; Tokita S; Kikuchi Y; Takaya A; Hirohashi Y; Tsukahara T; Terui T; Ishitani K; Hata F; Takemasa I; Miyazaki A; Hiratsuka H; Sato N; Torigoe T
    Cancer Immunol Res; 2018 Mar; 6(3):358-369. PubMed ID: 29371260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression.
    Jimenez P; Cantón J; Concha A; Cabrera T; Fernández M; Real LM; García A; Serrano A; Garrido F; Ruiz-Cabello F
    Cancer Immunol Immunother; 2000 Mar; 48(12):684-90. PubMed ID: 10752476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.